Lead Product(s) : Rose Bengal Disodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $3.0 million
Deal Type : Financing
Provectus Announces Seed Financing for VisiRose, Eye Drug Spinoff Company
Details : The financing is intended to support the clinical development of VisiRose’s formulated Rose Bengal Disodium for the treatment of infectious keratitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 14, 2025
Lead Product(s) : Rose Bengal Disodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $3.0 million
Deal Type : Financing
Lead Product(s) : Rose Bengal Disodium
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver
Details : Rose Bengal Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neuroendocrine Tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 26, 2016
Lead Product(s) : Rose Bengal Disodium
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rose Bengal Disodium
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
Details : Rose Bengal Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 23, 2015
Lead Product(s) : Rose Bengal Disodium
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rose Bengal Disodium
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10
Details : Rose Bengal Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 22, 2014
Lead Product(s) : Rose Bengal Disodium
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rose Bengal Disodium
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Provectus Biopharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study
Details : Rose Bengal Disodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 04, 2013
Lead Product(s) : Rose Bengal Disodium
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Provectus Biopharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable